6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluation of Quantitative Decision‐Making for Rhythm Management of Atrial Fibrillation Using Tabular Q‐Learning

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Rhythm management is a complex decision for patients with atrial fibrillation (AF). Although clinical trials have identified subsets of patients who might benefit from a given rhythm‐management strategy, for individual patients it is not always clear which strategy is expected to have the greatest mortality benefit or durability.

          Methods and Results

          In this investigation 52 547 patients with a new atrial fibrillation diagnosis between 2010 and 2020 were retrospectively identified. We applied a type of artificial intelligence called tabular Q‐learning to identify the optimal initial rhythm‐management strategy, based on a composite outcome of mortality, change in treatment, and sustainability of the given treatment, termed the reward function. We first applied an unsupervised learning algorithm using a variational autoencoder with K‐means clustering to cluster atrial fibrillation patients into 8 distinct phenotypes. We then fit a Q‐learning algorithm to predict the best outcome for each cluster. Although rate‐control strategy was most frequently selected by treating providers, the outcome was superior for rhythm‐control strategies across all clusters. Subjects in whom provider‐selected treatment matched the Q‐table recommendation had fewer total deaths (4 [8.5%] versus 473 [22.4%], odds ratio=0.32, P=0.02) and a greater reward ( P=4.8×10 −6). We then demonstrated application of dynamic learning by updating the Q‐table prospectively using batch gradient descent, in which the optimal strategy in some clusters changed from cardioversion to ablation.

          Conclusions

          Tabular Q‐learning provides a dynamic and interpretable approach to apply artificial intelligence to clinical decision‐making for atrial fibrillation. Further work is needed to examine application of Q‐learning prospectively in clinical patients.

          Related collections

          Most cited references63

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Highly accurate protein structure prediction with AlphaFold

          Proteins are essential to life, and understanding their structure can facilitate a mechanistic understanding of their function. Through an enormous experimental effort 1 – 4 , the structures of around 100,000 unique proteins have been determined 5 , but this represents a small fraction of the billions of known protein sequences 6 , 7 . Structural coverage is bottlenecked by the months to years of painstaking effort required to determine a single protein structure. Accurate computational approaches are needed to address this gap and to enable large-scale structural bioinformatics. Predicting the three-dimensional structure that a protein will adopt based solely on its amino acid sequence—the structure prediction component of the ‘protein folding problem’ 8 —has been an important open research problem for more than 50 years 9 . Despite recent progress 10 – 14 , existing methods fall far short of atomic accuracy, especially when no homologous structure is available. Here we provide the first computational method that can regularly predict protein structures with atomic accuracy even in cases in which no similar structure is known. We validated an entirely redesigned version of our neural network-based model, AlphaFold, in the challenging 14th Critical Assessment of protein Structure Prediction (CASP14) 15 , demonstrating accuracy competitive with experimental structures in a majority of cases and greatly outperforming other methods. Underpinning the latest version of AlphaFold is a novel machine learning approach that incorporates physical and biological knowledge about protein structure, leveraging multi-sequence alignments, into the design of the deep learning algorithm. AlphaFold predicts protein structures with an accuracy competitive with experimental structures in the majority of cases using a novel deep learning architecture.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mastering the game of Go with deep neural networks and tree search.

            The game of Go has long been viewed as the most challenging of classic games for artificial intelligence owing to its enormous search space and the difficulty of evaluating board positions and moves. Here we introduce a new approach to computer Go that uses 'value networks' to evaluate board positions and 'policy networks' to select moves. These deep neural networks are trained by a novel combination of supervised learning from human expert games, and reinforcement learning from games of self-play. Without any lookahead search, the neural networks play Go at the level of state-of-the-art Monte Carlo tree search programs that simulate thousands of random games of self-play. We also introduce a new search algorithm that combines Monte Carlo simulation with value and policy networks. Using this search algorithm, our program AlphaGo achieved a 99.8% winning rate against other Go programs, and defeated the human European Go champion by 5 games to 0. This is the first time that a computer program has defeated a human professional player in the full-sized game of Go, a feat previously thought to be at least a decade away.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

              The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin. In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism. In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 to 0.96; P<0.001 for noninferiority). In the intention-to-treat analysis, the primary end point occurred in 269 patients in the rivaroxaban group (2.1% per year) and in 306 patients in the warfarin group (2.4% per year) (hazard ratio, 0.88; 95% CI, 0.74 to 1.03; P<0.001 for noninferiority; P=0.12 for superiority). Major and nonmajor clinically relevant bleeding occurred in 1475 patients in the rivaroxaban group (14.9% per year) and in 1449 in the warfarin group (14.5% per year) (hazard ratio, 1.03; 95% CI, 0.96 to 1.11; P=0.44), with significant reductions in intracranial hemorrhage (0.5% vs. 0.7%, P=0.02) and fatal bleeding (0.2% vs. 0.5%, P=0.003) in the rivaroxaban group. In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials.gov number, NCT00403767.).
                Bookmark

                Author and article information

                Contributors
                michael.a.rosenberg@cuanschutz.edu
                Journal
                J Am Heart Assoc
                J Am Heart Assoc
                10.1002/(ISSN)2047-9980
                JAH3
                ahaoa
                Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
                John Wiley and Sons Inc. (Hoboken )
                2047-9980
                29 April 2023
                02 May 2023
                : 12
                : 9 ( doiID: 10.1002/jah3.v12.9 )
                : e028483
                Affiliations
                [ 1 ] Department of Cardiac Electrophysiology University of Colorado Anschutz Medical Campus Aurora CO USA
                [ 2 ] Department of Computer Science University of Colorado Denver CO USA
                [ 3 ] Department of Cardiac Electrophysiology Rocky Mountain Regional VA Healthcare System Aurora CO USA
                [ 4 ] Department of Cardiac Electrophysiology Denver Health Medical Center Denver CO USA
                Author notes
                [*] [* ]Correspondence to: Michael A. Rosenberg, MD, Department of Cardiac Electrophysiology, University of Colorado Anschutz Medical Center, Aurora, CO 80045. Email: michael.a.rosenberg@ 123456cuanschutz.edu
                Author information
                https://orcid.org/0000-0002-8073-5773
                https://orcid.org/0000-0001-5018-7596
                https://orcid.org/0000-0002-5994-7480
                https://orcid.org/0000-0002-6435-5746
                https://orcid.org/0000-0003-1937-4582
                https://orcid.org/0000-0002-5662-8505
                https://orcid.org/0000-0002-8514-1165
                https://orcid.org/0000-0003-4102-9873
                https://orcid.org/0000-0002-6708-1648
                Article
                JAH38405 JAHA/2022/028483
                10.1161/JAHA.122.028483
                10227221
                37119087
                cc9b4854-2a42-4e2c-90fc-fd21231ef337
                © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 13 October 2022
                : 21 March 2023
                Page count
                Figures: 2, Tables: 3, Pages: 45, Words: 11478
                Categories
                Original Research
                Original Research
                Arrhythmia and Electrophysiology
                Custom metadata
                2.0
                02 May 2023
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.8 mode:remove_FC converted:07.05.2023

                Cardiovascular Medicine
                artificial intelligence,atrial fibrillation,q‐learning,rate control,reinforcement learning,rhythm control,unsupervised learning,electrophysiology

                Comments

                Comment on this article